Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03148418 · ClinicalTrials.gov registry record · Phase 3
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
A Phase 3 study of Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 382
- Enrollment target
- 20
- Study locations
NCT03148418: Active Phase 3 study of Cancer, sponsored by Hoffmann-La Roche.
NCT03148418 is a Phase 3 study of Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 382 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03148418, a Phase 3 study of Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 382 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive study treatment at the time of the parent-study closure and do not have access to the study treatment locally are eligible for continued treatment in the extension study. Dosing regimen for a given participant and indication will be the same or equivalent to the respective parent study protocol. Study treatment in the extension study can continue until disease progression or beyond if the patient continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; patient non-compliance; or study termination by the Sponsor, whichever occurs first.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
Study Locations (20)
Illinois
- Northwestern University - Chicago
- Rush University Medical Center - Chicago
- University Of Chicago Medical Center - Chicago
- Ingalls Memorial Hospital - Harvey
- Illinois Cancer Care - Peoria
Florida
- Florida Cancer Specialists - Fort Myers (Broadway) - Fort Myers
- Hematology Oncology Associates of the Treasure Coast - Port Saint Lucie
- Florida Cancer Specialists. - St. Petersburg
- H. Lee Moffitt Cancer Center and Research Inst. - Tampa
California
- Angeles Clinic & Rsch Inst - Los Angeles
- UCLA - Los Angeles
- Kaiser Permanente - San Diego (Zion Ave) - San Marcos
Colorado
- University Of Colorado - Aurora
- Rocky Mountain Cancer Ctr - Denver (Williams) - Denver
Arizona
- HonorHealth Research Institute ? Bisgrove - Scottsdale
Connecticut
- Smilow Cancer Hospital at Yale New Haven - New Haven
District of Columbia
- Georgetown University Medical Center Lombardi Cancer Center - Washington D.C.
Georgia
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 382 participants |
| Start Date | 2017-09-20 |
| Est. Completion | 2030-03-06 |
| Phase | Phase 3 |
What the registry record for NCT03148418 still lists
NCT03148418 is an interventional study that assigns participants to a tested intervention. The registered 382 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT03148418 names 20 study sites across 10 states, led by Illinois, Florida, California.
Frequently Asked Questions
What is clinical trial NCT03148418 about?
NCT03148418 is a clinical study titled "A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)". This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive s...
What is the current status of trial NCT03148418?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 382 participants. The study started on 2017-09-20. Estimated completion is 2030-03-06.
What conditions does trial NCT03148418 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT03148418?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT03148418?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03148418 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03148418's enrollment target sits among peer trials
382 157th of 615 higher than 459 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
RECRUITING · Phase 3
-
DOAC - Dosing Options in AntiCoagulation Prophylaxis
RECRUITING · Phase 3
-
Abatacept in Immune Checkpoint Inhibitor Myocarditis
RECRUITING · Phase 3
-
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
RECRUITING · Phase 3
-
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
RECRUITING · Phase 3
-
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05677490 · 382 participants · Phase 3
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- NCT06196008 · 382 participants · NA
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
- NCT07100990 · 382 participants · Phase 3
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
- NCT06056830 · 383 participants · Phase 3
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI